速递｜14.2亿元甩卖口服胰岛素梦：华润踩雷十年止损

GLP1减重宝典02-14

整理 | GLP1减重宝典内容团队2月9日，华润医药公告拟在上海联合产权交易所以公开挂牌方式，出售所持合肥天麦生物约17.87%股权，挂牌底价约14.2亿元。对外界而言，这更像一次普通的资产处置；但放在时间轴上看，它是华润医药一段跨界豪赌的“清算时刻”。十年前，华润在寻求从传统分销与仿制药思路向生物制药转身时，选择了胰岛素这条确定性更强、利润更厚的赛道，并把最激进的筹码压在口服胰岛素上。如今，口服...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2611121824?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-14 22:57","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2611121824","market":"hk","top_or_hot":-1,"title":"速递｜14.2亿元甩卖口服胰岛素梦：华润踩雷十年止损","media":"GLP1减重宝典","content":"<div>\n<p>整理 | GLP1减重宝典内容团队2月9日，华润医药公告拟在上海联合产权交易所以公开挂牌方式，出售所持合肥天麦生物约17.87%股权，挂牌底价约14.2亿元。对外界而言，这更像一次普通的资产处置；但放在时间轴上看，它是华润医药一段跨界豪赌的“清算时刻”。十年前，华润在寻求从传统分销与仿制药思路向生物制药转身时，选择了胰岛素这条确定性更强、利润更厚的赛道，并把最激进的筹码压在口服胰岛素上。如今，口服...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423115497a6393b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>速递｜14.2亿元甩卖口服胰岛素梦：华润踩雷十年止损</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n速递｜14.2亿元甩卖口服胰岛素梦：华润踩雷十年止损\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-14 22:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423115497a6393b&s=b><strong>GLP1减重宝典</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>整理 | GLP1减重宝典内容团队2月9日，华润医药公告拟在上海联合产权交易所以公开挂牌方式，出售所持合肥天麦生物约17.87%股权，挂牌底价约14.2亿元。对外界而言，这更像一次普通的资产处置；但放在时间轴上看，它是华润医药一段跨界豪赌的“清算时刻”。十年前，华润在寻求从传统分销与仿制药思路向生物制药转身时，选择了胰岛素这条确定性更强、利润更厚的赛道，并把最激进的筹码压在口服胰岛素上。如今，口服...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423115497a6393b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516422440.USD","symbol_name":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423115497a6393b&s=b","article_id":"2611121824","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021423115497a6393b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611121824","pubTimestamp":1771081043,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"如今，口服胰岛素海外三期失败、国内上市受挫、胰岛素集采重塑格局，叠加华润体系内的业绩压力与资源再分配，天麦生物从曾被寄予厚望的里程碑，变成了必须止损的包袱。华润与天麦的交集始于2016年。回到天麦案例，华润的撤退并不等同于口服胰岛素彻底没有未来，更不意味着企业本身失去全部价值。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU2088748376.SGD":"Eastspring Investments - Asia Real Estate Multi Asset Income Cl ASDM SGD-H","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0287142896.SGD":"Fidelity China Focus A-SGD","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU2088747998.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC","LU0173614495.USD":"富达中国焦点A","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU1366334651.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"I\" (USD) INC","LU0359201612.USD":"贝莱德中国基金A2","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU0738912210.USD":"Blackrock Asia Pacific Equity Income A6 USD","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0594300419.USD":"富达中国消费基金A","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU2088748020.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"ADM\" (USD) INC A","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU0048597586.USD":"富达亚洲焦点A","LU2088747725.USD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"A\" (USD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","SG9999009997.SGD":"United Asia Pacific Real Estate Income Acc SGD","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","SG9999010052.SGD":"United Asia Pacific Real Estate Income Dis SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","BK1240":"房地产开发","01109":"华润置地","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","BK1555":"内房股","LU2088748293.HKD":"EASTSPRING INVESTMENTS ASIA REAL ESTATE MULTI ASSE \"AHD\" (HKD) INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC"},"translate_title":"Express | 1.42 billion yuan sale of oral insulin dream: China Resources stopped losses after ten years of thunder","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01109":0.9},"content_text":"整理 | GLP1减重宝典内容团队2月9日，华润医药公告拟在上海联合产权交易所以公开挂牌方式，出售所持合肥天麦生物约17.87%股权，挂牌底价约14.2亿元。对外界而言，这更像一次普通的资产处置；但放在时间轴上看，它是华润医药一段跨界豪赌的“清算时刻”。十年前，华润在寻求从传统分销与仿制药思路向生物制药转身时，选择了胰岛素这条确定性更强、利润更厚的赛道，并把最激进的筹码压在口服胰岛素上。如今，口服胰岛素海外三期失败、国内上市受挫、胰岛素集采重塑格局，叠加华润体系内的业绩压力与资源再分配，天麦生物从曾被寄予厚望的里程碑，变成了必须止损的包袱。华润与天麦的交集始于2016年。彼时，天麦生物的“故事”很清晰：一方面做胰岛素及类似物的研发与产业化，另一方面通过其子公司天汇生物与以色列Oramed绑定，获得口服胰岛素胶囊ORMD-0801在国内的引进与推进空间。口服胰岛素之所以被长期追逐，是因为它满足糖尿病治疗最直观的痛点：把长期注射变成口服，理论上能显著改善依从性，扩大用药人群，并在商业化上形成对注射制剂的“体验碾压”。但这条路的难度也同样极端：胰岛素是蛋白质，进入胃肠道会被酸性环境和蛋白酶快速降解；即便穿过消化系统，如何跨越肠上皮进入体循环、在可控剂量下实现稳定生物利用度，都是接近基础科学难题的工程挑战。换句话说，口服胰岛素不是把针换成药片那么简单，而是在体内重新修一条输送高速路。正因如此，口服胰岛素的“稀缺性”曾被无限放大。天麦及其合作方在一段时间内被视为最接近商业化的玩家之一，市场也多次出现并购传闻。但现实进展并没有按资本期待的节奏推进。公开信息曾显示，天麦较晚才拿到注射用胰岛素相关批件，早期营收规模极小；在国内胰岛素集采落地后，原本被认为“现金牛”的行业逻辑被改写，价格快速下沉、份额向规模与渠道能力更强的头部集中，中小参与者即便产品获批，也很难在量与价上同时站稳。这意味着，华润最初设想的“口服做成就跃迁，口服做不成也能靠注射赚钱”的双保险，在集采后的现实里变得并不牢靠：注射端的回报率与确定性被明显压缩，而口服端又迟迟无法兑现。转折点出现在2023年。Oramed披露ORMD-0801的海外三期多中心临床未能达成主要终点和次要终点，这几乎等于对口服胰岛素的核心叙事做了一次硬碰硬的挑战。即便在这一背景下，天麦体系仍试图继续推进国内路径，并对外保持积极预期；但临床失败带来的不仅是产品层面的不确定性，还会影响监管沟通、投资者信心以及后续资金安排。2025年底，天汇生物的ORMD-0801国内上市计划最终折戟，口服胰岛素这条线基本失去短期兑现可能。对华润而言，继续持有的意义迅速下降：如果最核心的差异化资产无法落地，剩下的就只能回到注射胰岛素与代工能力等较为同质化的竞争维度，而这些维度恰好处在集采持续挤压与头部强者恒强的周期中。值得注意的是，天麦并非没有自救动作。在口服胰岛素遭遇挫折后，企业也尝试追赶新的热门方向，例如引入GLP-1类似物概念，试图以新管线重建估值与谈判空间。但GLP-1这条赛道的门槛与竞争强度已经与十年前的胰岛素截然不同：国际巨头与国内头部在临床、产能、渠道、支付与推广体系上形成了高度集成的壁垒，后来者要么在分子机制、给药方式、适应症组合上做出足够差异化，要么就得付出极高的市场费用，在红海里换一点份额。对华润来说，最可控的打法不是继续押注一家前景未明的参股公司，而是利用自身更强的商业化与渠道能力，去绑定更有确定性的产品资产。因此，华润三九在2025年与博瑞医药就BGM0504达成合作，支付研发里程碑与后续商业化安排，本质是一种“用交易换确定性”的路径：不用承担一家企业多年沉没成本与技术路径风险，直接把资源放到更有胜率的标的上。华润此时选择挂牌退出，也绕不开财务与组织层面的压力。过去几年，华润系医药资产分布广、并购动作多，面对零售终端承压、中成药集采推进、器械企业波动、并购整合影响利润等因素，集团层面的资金与业绩考核更强调效率与回报。在这种语境下，天麦这种难以贡献现金流、核心产品又受挫的资产，很难再获得持续耐心。挂牌底价14.2亿元并不代表最终成交价，但它清晰释放信号：华润更愿意把资源集中到能够兑现增长、能够被体系消化的方向，而不是继续在“可能改变世界”的高风险项目上消耗管理与资金。回到天麦案例，华润的撤退并不等同于口服胰岛素彻底没有未来，更不意味着企业本身失去全部价值。它更像是一场现实主义的再定价：在集采常态化、创新药竞争白热化、资金更讲效率的周期里，大型医药集团要为每一笔资本占用寻找更强的回报解释。曾经的里程碑，可以是战略跃迁的入口，也可能在十年后变成必须结清的一笔历史成本。挂牌只是一个动作，背后真正改变的，是对风险、时间和确定性的重新排序。*本文仅供医疗卫生专业人士参考","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611121824","isCrawlerRequest":true}